Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$1.49 USD
+0.04 (2.76%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.47 -0.02 (-1.34%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HOWL 1.49 +0.04(2.76%)
Will HOWL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOWL
Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Other News for HOWL
180 Bullish Setup appears for HOWL after 2.76% move
Is HOWL building bullish momentum? Pocket Pivot shows up after advancing 3.57%
Bollinger Band Squeeze appears for HOWL after 3.45% move
H.C. Wainwright Sticks to Its Buy Rating for Werewolf Therapeutics (HOWL)
HOWL forms 180 Bullish Setup on September 16